Renal Archives - Insights

Rare kidney disease diagnostic advances recognized for clinical impact

Jessie Fenske — Thu, 02 Apr 2026 13:00:00 +0000

Research improves the diagnosis of rare Birt-Hogg-Dubé syndrome, closing genetic testing gaps, guiding care, and earning recognition as a top paper.

The post Rare kidney disease diagnostic advances recognized for clinical impact appeared first on Insights.

Cultivating a comprehensive test menu for organ transplant patients

Chris Bahnsen — Fri, 30 Jan 2026 14:00:00 +0000

Viral and pharmacogenomic testing help clinicians detect infection early, tailor immunosuppression, and improve long-term outcomes for organ transplant recipients.

The post Cultivating a comprehensive test menu for organ transplant patients appeared first on Insights.

Accurate Kidney Stone Analysis

MCL Education — Wed, 08 Oct 2025 16:23:51 +0000

This microlearning will familiarize users on MCL's AI-augmented kidney stone test along with the proper procedures for collecting and processing kidney stones to provide accurate, cost-effective, and timely analysis of the stones.

The post Accurate Kidney Stone Analysis appeared first on Insights.

Assay Aids Diagnosis of Resistant Hypertension: John Lieske, M.D., and Sandra Taler, M.D.

Barbara J. Toman — Tue, 24 Jun 2025 13:00:00 +0000

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of whether patients are actually absorbing their medications or whether a new approach might be needed.

The post Assay Aids Diagnosis of Resistant Hypertension: John Lieske, M.D., and Sandra Taler, M.D. appeared first on Insights.

Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D.

Barbara J. Toman — Tue, 21 Jan 2025 14:00:00 +0000

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

The post Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. appeared first on Insights.

Test for LDL subtype helps manage coronary risk: Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D.

Barbara J. Toman — Tue, 08 Aug 2023 13:00:00 +0000

Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.

The post Test for LDL subtype helps manage coronary risk: Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D. appeared first on Insights.

Results report simplifies urine test interpretation: John Lieske, M.D.

Barbara J. Toman — Tue, 04 Jul 2023 13:00:00 +0000

John Lieske, M.D., explains why it's now easier for clinicians to pull information from Mayo Clinic Laboratories' supersaturation test report. An updated format summarizes complex information to help guide the treatment of kidney stones.

The post Results report simplifies urine test interpretation: John Lieske, M.D. appeared first on Insights.

Applying Mayo Clinic MASSFIX to Urine Samples

MCL Education — Mon, 22 May 2023 10:00:00 +0000

In this month's "Hot Topic," David Murray, M.D., Ph.D., reviews the role of urine testing for monoclonal gammopathies and discusses Mayo Clinic’s use of MASSFIX to replace traditional immunofixation testing.

The post Applying Mayo Clinic MASSFIX to Urine Samples appeared first on Insights.

New AI-augmented test refines kidney stone analysis

Nicole Holman — Wed, 10 May 2023 13:00:00 +0000

Since March 2019, Paul Jannetto, Ph.D., director of the Metals Laboratory at Mayo Clinic, along with his colleagues across the enterprise and his laboratory staff, have developed, validated, and implemented an artificial intelligence (AI)-augmented test with algorithms designed to interpret kidney stone FTIR spectra. With more than 90,000 kidney stones analyzed each year at Mayo Clinic, this new AI-assisted test has streamlined lab processes and improved patient care.

The post New AI-augmented test refines kidney stone analysis appeared first on Insights.

State-of-the-art genetics panel optimizes kidney disease treatment

Barbara J. Toman — Tue, 30 Aug 2022 13:00:00 +0000

Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive, accurate and actionable results. Identifying a genetic cause helps guide the complex decisions involved with treating kidney disease.

The post State-of-the-art genetics panel optimizes kidney disease treatment appeared first on Insights.